Estrogen receptor drugs for Breast Cancer
6 tracked Estrogen receptor drugs in the Breast Cancer race. The class explanation lives on the Estrogen receptor page; the full indication pipeline across every mechanism is on the Breast Cancer page.
6 approved / phase 4
Head-to-head evidence: Camizestrant vs Elacestrant · Camizestrant vs Fulvestrant · Camizestrant vs Imlunestrant · Camizestrant vs Tamoxifen (Soltamox) · Camizestrant vs Vepdegestrant · Elacestrant vs Fulvestrant